pharmaphorum April 24, 2024
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fibrosis and solid tumours.
It is the latest in a recent string of nine-figure private rounds for US biotechs that point to an improving environment for access to financing, coming after others from TORL BioTherapeutics, Nvelop Therapeutics, Seaport Therapeutics, Obsidian Therapeutics, Alterome, and Diagonal Therapeutics in just the last few weeks.
San Diego-based Endeavor recently completed a phase 2a trial of its lead drug ENV-101 in idiopathic pulmonary fibrosis (IPF) and has said the preliminary results suggest it could be the first disease-modifying therapy for the disease. The full data from the study has not yet been...
Today's Sponsors
Today's Sponsor